Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 7, 2012, Pages 1197-1203

  Dong, Ningning ^a   Yu, Jing ^a   Wang, Chaoying ^a   Zheng, Xiaohui ^a   Wang, Zheng ^a   Di, Lijun ^a   Song, Guohong ^a   Zhu, Budong ^a   Li, Che ^a   Jia, Jun ^a   Jiang, Hanfang ^a   Zhou, Xinna ^a   Wang, Xiaoli ^a   Ren, Jun ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Breast cancer; Chemotherapy; Cytochrome P450; Polymorphism

Indexed keywords

CAPECITABINE; CYTOCHROME P450 1A1; DOCETAXEL;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CYP1A1 GENE; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MUTATOR GENE; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PHARMACOGENETICS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 84864335747     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1183-5     Document Type: Article

References (36)

1. Aktas D, Guney I, Alikasifoglu M et al (2002) CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm. Gynecol Oncol 86:124-128 (Pubitemid 34953492)
2. Bray J, Sludden J, Griffin MJ et al (2010) Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 102:1003-1009
3. Canova C, Hashibe M, Simonato L et al (2009) Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. Cancer Res 69:2956-2965
4. Chan S, Romieu G, Huober J et al (2009) Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 27:1753-1760
5. Chen Z, Li Z, Niu X et al (2011) The effect of CYP1A1 polymorphisms on the risk of lung cancer: a global meta-analysis based on 71 casecontrol studies. Mutagenesis 26:437-446
6. Cosma G, Crofts F, Taioli E et al (1993) Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health 40:309-316 (Pubitemid 23344356)
7. Goetz MP, Rae JM, Suman VJ et al (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318
8. Gor PP, Su HI, Gray RJ et al (2010) Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res 12:R26
9. Harbeck N, Salem M, Nitz U et al (2010) Personalized treatment of early-stage breast cancer: present concepts and future directions. Cancer Treat Rev 36:584-594
10. Ingelman-Sundberg M (2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 25:193-200 (Pubitemid 38519910)
11. Ingelman-Sundberg M, Sim SC, Gomez A et al (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526 (Pubitemid 350116943)
12. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
13. Justenhoven C, Winter S, Hamann U et al (2010) The frameshift polymorphism CYP3A43-74-delA is associated with poor differentiation of breast tumors. Cancer 116:5358-5364
14. Kim HN, Kim NY, Yu L et al (2009) Polymorphisms of drugmetabolizing genes and risk of non-Hodgkin lymphoma. Am J Hematol 84:821-825
15. Kiss I, Orsós Z, Gombos K et al (2007) Association between allelic polymorphisms of metabolizing enzymes (CYP 1A1, CYP 1A2, CYP 2E1, mEH) and occurrence of colorectal cancer in Hungary. Anticancer Res 27:2931-2937 (Pubitemid 47228023)
16. Kiyotani K, Mushiroda T, Imamura CK et al (2010) Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 28:1287-1293
17. Ma X, Qi X, Chen C et al (2010) Association between CYP19 polymorphisms and breast cancer risk: results from 10,592 cases and 11,720 controls. Breast Cancer Res Treat 122:495-501
18. Marsh S, Somlo G, Li X et al (2007) Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 7:362-365 (Pubitemid 47484774)
19. Mehta R, Jain RK, Badve S (2011) Personalized medicine: the road ahead. Clin Breast Cancer 11:20-26
20. Michalaki V, Gennatas S, Gennatas K (2009) Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results. Anticancer Drugs 20:204-207
21. Moreno-Aspitia A, Perez EA (2009) Anthracycline- and/or taxaneresistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. Clin Ther 31:1619-1640
22. Murata M, Watanabe M, Yamanaka M et al (2001) Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett 165:171-177 (Pubitemid 32244174)
23. Musolino A, Naldi N, Bortesi B et al (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789-1796
24. O'Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline- pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812-2823 (Pubitemid 34651510)
25. Petros WP, Hopkins PJ, Spruill S et al (2005) Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol 23:6117-6125
26. Ruiter R, Bijl MJ, van Schaik RH et al (2010) CYP2C192 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics 11:1367-1375
27. Schroth W, Antoniadou L, Fritz P et al (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187-5193 (Pubitemid 350232249)
28. Sergentanis TN, Economopoulos KP (2010) Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 122:459-469
29. Taspinar M, Aydos SE, Comez O et al (2008) CYP1A1, GST gene polymorphisms and risk of chronic myeloid leukemia. Swiss Med Wkly 138:12-17 (Pubitemid 351192768)
30. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
31. Thussbas C, Nahrig J, Streit S et al (2006) FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 24:3747-3755 (Pubitemid 46622313)
32. Tsuchiya Y, Kiyohara C, Sato T et al (2007) Polymorphisms of cytochrome P450 1A1, glutathione S-transferase class mu, and tumour protein p53 genes and the risk of developing gallbladder cancer in Japanese. Clin Biochem 40:881-886 (Pubitemid 47077408)
33. Watson RG, McLeod HL (2011) Pharmacogenomic contribution to drug response. Cancer J 17:80-88
34. Xu Y, Yao L, Ouyang T et al (2005) p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 11:7328-7333 (Pubitemid 41507691)
35. Yang J, Qian LX, Wu HF et al (2006) Genetic polymorphisms in the cytochrome P450 1A1 and 2E1 genes, smoking, drinking and prostate cancer susceptibility: a case-control study in a Han nationality population in Southern China. Int J Urol 13:773-780 (Pubitemid 43926771)
36. Zhuo WL, Zhang YS, Wang Y et al (2009) Association studies of CYP1A1 and GSTM1 polymorphisms with esophageal cancer risk: evidence-based meta-analyses. Arch Med Res 40:169-179